Efficacy, Tolerability and Virological Consequences of Long-Term Use of Unboosted Atazanavir Plus 2 NRTIs in HIV-Infected Patients

By  

Current HIV Research, Vol. 12, Iss. 5, 2014-09 ,pp. : 339-346

Bentham Science Publishers

Access to resources Recommend Favorite

Endothelial function in HIV-infected patients switching from a boosted protease inhibitor-based regimen to raltegravir: a substudy of the SPIRAL study

By Masiá Mar   Martínez Esteban   Padilla Sergio   Gatell José M.   Gutiérrez Félix  

Journal of Antimicrobial Chemotherapy, Vol. 68, Iss. 2, 2013-02 ,pp. : 409-413

Oxford University Press

Access to resources Recommend Favorite

Sildenafil Plasma Concentrations in Two HIV Patients with Pulmonary Hypertension Treated with Ritonavir-Boosted Protease Inhibitors

By  

Current HIV Research, Vol. 10, Iss. 2, 2012-03 ,pp. : 162-164

Bentham Science Publishers

Access to resources Recommend Favorite

Sialolithiasis in an HIV-1-infected patient treated with atazanavir/ritonavir monotherapy

By Lê Minh P.   Stitou Hind   Soulie Cathia   Katlama Christine   Peytavin Gilles  

Journal of Antimicrobial Chemotherapy, Vol. 68, Iss. 3, 2013-03 ,pp. : 727-729

Oxford University Press

Access to resources Recommend Favorite

Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine

By Uy Jonathan   Yang Rong   Wirtz Victoria   Sheppard Louise   Farajallah Awny   McGrath Donnie  

AIDS Care, Vol. 23, Iss. 11, 2011-11 ,pp. : 1500-1504

Routledge Ltd

Access to resources Recommend Favorite